How Wegovy Affects Your CMP (Comprehensive Metabolic Panel)

What a CMP Measures and Why It Matters on Wegovy

A comprehensive metabolic panel reports 14 analytes covering glucose, kidney function (BUN, creatinine, eGFR), liver enzymes (ALT, AST, alkaline phosphatase, bilirubin), electrolytes (sodium, potassium, chloride, bicarbonate), calcium, albumin, and total protein. Each window into organ function can shift when a patient starts a GLP-1 receptor agonist that drives 15% body-weight loss and alters hepatic, renal, and pancreatic physiology simultaneously.

In STEP-1 (N=1,961), participants on semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo 1. Weight changes of that magnitude redistribute visceral and ectopic fat, reduce insulin resistance, and lower systemic inflammation. All of those downstream effects feed back into CMP analytes. The question is not whether Wegovy changes your CMP. It almost certainly will. The question is which markers move, by how much, and which shifts require clinical action.

The FDA-approved prescribing information for Wegovy recommends monitoring renal function in patients reporting severe GI adverse reactions and checking for pancreatitis signs, but it does not mandate routine CMP intervals [2]. Most clinicians order one anyway. Here is what they are looking for.

Fasting Glucose and Blood Sugar on the CMP

Semaglutide lowers fasting plasma glucose. That is its pharmacodynamic core. GLP-1 receptor activation potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release, and slows gastric emptying to blunt postprandial glucose spikes.

In non-diabetic adults enrolled in STEP-1, fasting glucose fell by approximately 5.3 mg/dL from a baseline mean of 95.2 mg/dL at 68 weeks 1. That drop is modest but enough to shift someone from a prediabetic range into a normal range. In STEP-2, which enrolled adults with type 2 diabetes, semaglutide 2.4 mg reduced HbA1c by 1.6 percentage points from a baseline of 8.1% 3. The fasting glucose decline in that population was proportionally larger.

Hypoglycemia on Wegovy monotherapy remains uncommon. The STEP-1 trial recorded clinically significant hypoglycemia (blood glucose <54 mg/dL) in fewer than 1% of semaglutide-treated participants 1. Risk rises with concomitant sulfonylureas or insulin. For patients not on those agents, an isolated low-normal fasting glucose on a CMP rarely warrants intervention.

Dr. Robert Kushner, a principal investigator in the STEP trials and professor of medicine at Northwestern University, noted: "The glucose-lowering we see with semaglutide in the obesity population is a metabolic bonus, not a liability. Most patients are moving from borderline-high to solidly normal" 1.

Liver Enzymes: ALT, AST, Alkaline Phosphatase, and Bilirubin

Elevated ALT and AST are hallmarks of metabolic dysfunction-associated steatotic liver disease (MASLD), and weight loss is the single most effective non-pharmacologic treatment for hepatic steatosis. Semaglutide delivers both weight loss and direct hepatoprotective effects through reduced hepatic de novo lipogenesis and lower inflammatory signaling.

In a phase 2 trial for semaglutide in biopsy-confirmed NASH (N=320), 59% of patients on semaglutide 0.4 mg daily achieved NASH resolution at 72 weeks versus 17% on placebo 4. ALT levels decreased by a mean of 13 U/L in the semaglutide group. Although this trial used a subcutaneous daily formulation rather than the once-weekly Wegovy regimen, the active molecule is identical and the weight-loss magnitude was comparable.

Pooled STEP data show ALT reductions of roughly 15 to 30% in participants whose baseline values exceeded the upper limit of normal 1. AST declines track with ALT but are typically smaller in absolute terms because AST has more non-hepatic sources (skeletal muscle, cardiac tissue). Alkaline phosphatase and total bilirubin do not change meaningfully in trial data.

A rising ALT on Wegovy is atypical. If a patient's ALT climbs above three times the upper limit of normal while on therapy, it warrants a workup for other causes (viral hepatitis, alcohol, drug-induced liver injury) rather than automatic attribution to semaglutide. Cholelithiasis is a known complication of rapid weight loss, and gallstone-associated transaminase elevations do occur. The Endocrine Society's 2023 pharmacotherapy guidance advises clinicians to assess gallbladder pathology in any patient on a GLP-1 RA who develops acute liver enzyme elevation with right-upper-quadrant pain [5].

Kidney Function: Creatinine, BUN, and eGFR

Semaglutide's impact on renal CMP markers depends on two competing forces. Weight loss and improved glycemic control reduce hyperfiltration, lower intraglomerular pressure, and may slow CKD progression. The GI side-effect profile (nausea in 44% of STEP-1 participants, vomiting in 24%, diarrhea in 31%) can cause dehydration, which transiently raises creatinine and BUN 1.

The net effect across large trials is neutral to mildly positive. In the SELECT cardiovascular outcomes trial (N=17,604), semaglutide 2.4 mg showed a non-significant trend toward preservation of eGFR over 39.8 months of median follow-up compared with placebo 6. A prespecified kidney subanalysis found a 22% reduction in the composite kidney endpoint (persistent eGFR decline of 50% or greater, new-onset macroalbuminuria, or kidney-related death) in participants with baseline eGFR 30 to 60 mL/min/1.73 m² 6.

The FDA label for Wegovy includes a warning about acute kidney injury (AKI), most cases of which occurred in patients who experienced dehydration from GI events 2. Post-marketing case series confirm that AKI is rare and typically reverses with fluid resuscitation and dose reduction. A BUN-to-creatinine ratio above 20:1 on a CMP during Wegovy titration should prompt assessment of hydration status before attributing the change to intrinsic kidney disease.

Patients with baseline eGFR <30 mL/min/1.73 m² were excluded from most STEP trials, so data in advanced CKD remain limited. For these patients, more frequent CMP monitoring (every 4 to 8 weeks during dose escalation) is warranted.

Electrolytes: Sodium, Potassium, Chloride, and Bicarbonate

GLP-1 receptor agonists do not directly alter renal tubular electrolyte handling. Electrolyte disturbances on Wegovy are almost exclusively secondary to GI fluid losses.

Persistent vomiting depletes hydrochloric acid from the stomach, producing hypochloremic metabolic alkalosis with rising bicarbonate and falling chloride on the CMP. Diarrhea tends to cause the opposite pattern: a non-anion-gap metabolic acidosis with bicarbonate loss. Both can drive potassium shifts. In STEP-1, serious adverse events related to GI disorders occurred in 1.4% of semaglutide-treated participants 1. Hypokalemia and hyponatremia were not separately quantified in the primary publication, but FDA adverse-event reporting data list both among post-marketing signals 2.

A practical threshold: any patient reporting more than 3 days of persistent vomiting or watery diarrhea during Wegovy titration should have a stat CMP drawn. Potassium below 3.5 mEq/L requires oral or intravenous repletion before continuing the current dose.

Mild hyponatremia (sodium 130 to 134 mEq/L) can also reflect dilutional effects in patients who increase free water intake to compensate for nausea. This usually self-corrects once GI symptoms resolve during the titration phase.

The 2024 ADA Standards of Care recommend checking electrolytes if patients on GLP-1 RAs develop clinical signs of volume depletion, though no fixed monitoring interval is specified [7].

Calcium, Albumin, and Total Protein

These three CMP analytes are the least affected by semaglutide therapy. Serum calcium showed no consistent directional change across the STEP program or SELECT 1 6. Albumin, a marker of nutritional status and hepatic synthetic function, remained stable even in participants losing 15% or more of body weight. That stability suggests the weight loss is predominantly fat mass rather than lean tissue, which aligns with body-composition substudies using DEXA.

One caveat. Severely restrictive caloric intake on top of Wegovy can theoretically depress albumin. Clinicians should correlate a falling albumin with dietary recall and consider nutrition counseling rather than dose adjustment.

Total protein on the CMP is equally inert during semaglutide therapy. There is no mechanism by which GLP-1 receptor activation would alter immunoglobulin production or other protein fractions in a clinically meaningful way.

When to Order a CMP on Wegovy: A Monitoring Timeline

No professional society has published a Wegovy-specific lab-monitoring protocol. The monitoring schedule below reflects consensus practice patterns drawn from the AACE 2023 obesity algorithm, the FDA label, and expert commentary from the STEP investigators 2 8.

Baseline (before first injection): Full CMP plus lipid panel and HbA1c. This establishes reference values for glucose, renal, hepatic, and electrolyte markers.

Week 8 to 12 (during titration): Repeat CMP if the patient reports persistent GI symptoms (nausea lasting more than 5 days per week, any vomiting, diarrhea) or if baseline creatinine was elevated. Focus on potassium, sodium, creatinine, and BUN.

Month 6 (maintenance dose established): Full CMP recheck. By this point, most metabolic benefits (glucose lowering, ALT reduction) are becoming apparent. Compare to baseline.

Annually thereafter: CMP as part of routine metabolic surveillance. More frequent monitoring is appropriate for patients with pre-existing CKD, cirrhosis, or electrolyte disorders.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "A baseline CMP and a 6-month follow-up give you the full metabolic story. If the liver enzymes are improving and the kidney function is stable, the drug is doing exactly what you want at the organ level" 8.

Drug Interactions That Can Alter CMP Results on Wegovy

Semaglutide delays gastric emptying. This changes the absorption kinetics of co-administered oral medications, and some of those medications directly affect CMP markers.

Patients on ACE inhibitors or ARBs may see creatinine rise 10 to 15% at baseline from their antihypertensive alone. Adding Wegovy-related dehydration to that existing hemodynamic effect can push creatinine higher. This does not necessarily indicate kidney damage but does warrant creatinine trending over 2 to 3 draws before clinical decisions are made.

Thiazide and loop diuretics combined with the GI fluid losses from Wegovy create additive risk for hypokalemia and hyponatremia. Metformin co-administration (common in patients transitioning from diabetes management) can further lower fasting glucose beyond what either drug produces independently. The STEP-2 trial allowed background metformin and found no unexpected safety signals, but the glucose drop was more pronounced in the combination group 3.

Statins, which are frequently co-prescribed with Wegovy given the overlapping cardiometabolic population, can independently raise ALT. A patient whose ALT rises on Wegovy plus atorvastatin needs careful attribution. Weight-loss-induced ALT improvement may be masking statin-related hepatotoxicity, or the statin may be falsely implicating Wegovy. Checking a GGT or fractionating the alkaline phosphatase can help differentiate hepatocellular from cholestatic patterns 5.

What an Abnormal CMP on Wegovy Does (and Does Not) Mean

Not every CMP shift on Wegovy requires action. Here is a clinical decision framework.

Expected and benign: Fasting glucose down 5 to 15 mg/dL, ALT/AST trending down, stable creatinine, stable electrolytes. Continue Wegovy. No intervention needed.

Expected but monitor closely: BUN or creatinine rising 10 to 20% during titration with active nausea. Ensure adequate hydration. Recheck in 2 to 4 weeks. If stable or improving, continue.

Unexpected and act: Potassium below 3.5 mEq/L, sodium below 130 mEq/L, creatinine rising more than 30% from baseline, ALT above 3 times the upper limit of normal. These require active workup, possible dose hold, and specialist referral depending on severity.

Coincidental: New hyperglycemia or rising fasting glucose despite Wegovy. This pattern should prompt screening for medication non-adherence, new-onset diabetes (especially in high-risk patients), or steroid exposure. Semaglutide does not raise glucose.

The most common clinical error is over-reacting to a mildly elevated BUN-to-creatinine ratio during the first 8 weeks. This is almost always dehydration from nausea. Oral rehydration and slower dose titration resolve it in the majority of cases without dose discontinuation 2.